Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio ...

The clearance paves the way for the launch of Medtronic’s Smart MDI system, which combines its InPen and Simplera continuous ...

A new therapy for brittle type 1 diabetes, the only treatment currently approved by the U.S. Food and Drug Administration, is ...

Factors beyond carbohydrates have a substantial influence on blood glucose levels meaning current automated insulin delivery systems miss vital information required for glucose regulation, a new study ...

"They are challenged to do this relying solely on insulin, which is extremely difficult and is the principal therapy for people with T1D." An estimated 1.7 million adult Americans have T1D ...

Other companies are looking to administer insulin with needle-free devices, and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing ...